Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer

Q3 Medicine
E. Papadopoulos, Andy Kin On Wong, Sharon Hiu Ching Law, L. Zhang, H. Breunis, U. Emmenegger, S. Alibhai
{"title":"Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer","authors":"E. Papadopoulos, Andy Kin On Wong, Sharon Hiu Ching Law, L. Zhang, H. Breunis, U. Emmenegger, S. Alibhai","doi":"10.5489/cuaj.8803","DOIUrl":null,"url":null,"abstract":"Introduction: Sarcopenia is a predictor of clinical outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC); however, correlates and predictors of sarcopenia are poorly understood in this population. The aim of this study was to examine correlates and predictors of sarcopenia in men with mCRPC prior to treatment.\nMethods: A secondary analysis of an observational study was performed. Participants were receiving care for mCRPC at the Princess Margaret Cancer Centre. Sarcopenia was assessed prior to treatment and was defined as the combination of low grip strength (<35.5 kg), low gait speed (<0.8 m/s), and computed tomography-derived low muscle mass or density. Participants’ sociodemographic and clinical characteristics, comorbidity information, and clinically relevant blood markers were collected prior to treatment and were used to identify correlates and predictors of sarcopenia through Spearman correlations and multivariable logistic regression, respectively.\nResults: In total, 110 men had complete data on sarcopenia measures and were included in the analysis. Sarcopenia was identified in 30 (27.3%) participants. Pre-treatment sarcopenia was moderately correlated with dependence in one or more instrumental activities of daily living (IADLs) (r=0.412), Vulnerable Elders Survey-13 (r=0.404), and a lower hemoglobin (r=0.407 per 10 g/L decrease). In adjusted logistic regression, dependence in one or more IADLs (odds ratio [OR] 4.37, 95% confidence interval [CI] 1.37–13.86, p=0.012), and a 10 g/L decrease in hemoglobin (OR 1.70, 95% CI 1.13–2.57, p=0.012) were significantly associated with sarcopenia.\nConclusions: In settings where assessment of sarcopenia is not feasible, evaluation of IADLs and hemoglobin may be used to identify high-risk patients that can benefit from supportive care strategies aiming to improve muscle mass and function.","PeriodicalId":38001,"journal":{"name":"Canadian Urological Association Journal","volume":"51 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Urological Association Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5489/cuaj.8803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Sarcopenia is a predictor of clinical outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC); however, correlates and predictors of sarcopenia are poorly understood in this population. The aim of this study was to examine correlates and predictors of sarcopenia in men with mCRPC prior to treatment. Methods: A secondary analysis of an observational study was performed. Participants were receiving care for mCRPC at the Princess Margaret Cancer Centre. Sarcopenia was assessed prior to treatment and was defined as the combination of low grip strength (<35.5 kg), low gait speed (<0.8 m/s), and computed tomography-derived low muscle mass or density. Participants’ sociodemographic and clinical characteristics, comorbidity information, and clinically relevant blood markers were collected prior to treatment and were used to identify correlates and predictors of sarcopenia through Spearman correlations and multivariable logistic regression, respectively. Results: In total, 110 men had complete data on sarcopenia measures and were included in the analysis. Sarcopenia was identified in 30 (27.3%) participants. Pre-treatment sarcopenia was moderately correlated with dependence in one or more instrumental activities of daily living (IADLs) (r=0.412), Vulnerable Elders Survey-13 (r=0.404), and a lower hemoglobin (r=0.407 per 10 g/L decrease). In adjusted logistic regression, dependence in one or more IADLs (odds ratio [OR] 4.37, 95% confidence interval [CI] 1.37–13.86, p=0.012), and a 10 g/L decrease in hemoglobin (OR 1.70, 95% CI 1.13–2.57, p=0.012) were significantly associated with sarcopenia. Conclusions: In settings where assessment of sarcopenia is not feasible, evaluation of IADLs and hemoglobin may be used to identify high-risk patients that can benefit from supportive care strategies aiming to improve muscle mass and function.
患有转移性抗阉割前列腺癌的男性肌肉疏松症的相关因素和预测因素
简介:肌肉疏松症是预测转移性抗阉割前列腺癌(mCRPC)男性患者临床结果的一个指标;然而,对这一人群中肌肉疏松症的相关因素和预测因素却知之甚少。本研究的目的是在治疗前研究mCRPC男性患者肌肉疏松症的相关因素和预测因素:方法:对一项观察性研究进行二次分析。参与者在玛格丽特公主癌症中心接受了mCRPC治疗。在治疗前对肌肉疏松症进行了评估,并将其定义为低握力(<35.5 kg)、低步速(<0.8 m/s)和计算机断层扫描得出的低肌肉质量或密度。研究人员在治疗前收集了参与者的社会人口学和临床特征、合并症信息以及临床相关的血液指标,并通过斯皮尔曼相关性和多变量逻辑回归分别确定了肌少症的相关因素和预测因素:共有 110 名男性拥有完整的肌肉疏松症测量数据并被纳入分析。30名参与者(27.3%)发现了肌肉疏松症。治疗前肌肉疏松症与一种或多种日常生活工具(IADLs)依赖性(r=0.412)、《弱势老年人调查-13》(r=0.404)和血红蛋白降低(每降低 10 克/升,r=0.407)呈中度相关。在调整后的逻辑回归中,依赖一项或多项 IADLs(几率比 [OR] 4.37,95% 置信区间 [CI]1.37-13.86,p=0.012)和血红蛋白下降 10 g/L (OR 1.70,95% CI 1.13-2.57,p=0.012)与肌肉疏松症显著相关:结论:在无法对肌肉疏松症进行评估的情况下,可通过评估 IADLs 和血红蛋白来识别高危患者,这些患者可从旨在改善肌肉质量和功能的支持性护理策略中获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
167
期刊介绍: Published by the Canadian Urological Association, the Canadian Urological Association Journal (CUAJ) released its first issue in March 2007, and was published four times that year under the guidance of founding editor (Editor Emeritus as of 2012), Dr. Laurence H. Klotz. In 2008, CUAJ became a bimonthly publication. As of 2013, articles have been published monthly, alternating between print and online-only versions (print issues are available in February, April, June, August, October, and December; online-only issues are produced in January, March, May, July, September, and November). In 2017, the journal launched an ahead-of-print publishing strategy, in which accepted manuscripts are published electronically on our website and cited on PubMed ahead of their official issue-based publication date. By significantly shortening the time to article availability, we offer our readers more flexibility in the way they engage with our content: as a continuous stream, or in a monthly “package,” or both. CUAJ covers a broad range of urological topics — oncology, pediatrics, transplantation, endourology, female urology, infertility, and more. We take pride in showcasing the work of some of Canada’s top investigators and providing our readers with the latest relevant evidence-based research, and on being the primary repository for major guidelines and other important practice recommendations. Our long-term vision is to become an essential destination for urology-based research, education, and advocacy for both physicians and patients, and to act as a springboard for discussions within the urologic community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信